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Abstract
Certain missense mutations affecting LRP5 cause high bone mass (HBM) in humans. Based on in 
vitro evidence, HBM LRP5 receptors are thought to exert their effects by providing resistance to 
binding/inhibition of secreted LRP5 inhibitors such as sclerostin (SOST) and Dickkopf homolog-1 
(DKK1). We previously reported the creation of two Lrp5 HBM knock-in mouse models, in which 
the human p.A214V or p.G171V missense mutations were knocked into the endogenous Lrp5 
locus. To determine whether HBM knock-in mice are resistant to SOST- or DKK1-induced 
osteopenia, we bred Lrp5 HBM mice with transgenic mice that overexpress human SOST in 
osteocytes (8kbDmp1-SOST) or mouse DKK1 in osteoblasts and osteocytes (2.3kbCol1a1-Dkk1). 
We observed that the 8kbDmp1-SOST transgene significantly lowered whole body BMD, BMC, 
femoral and vertebral BV/TV, and periosteal BFR in wild-type mice but not in mice with Lrp5 
p.G171V and p.A214V alleles. The 2.3kbCol1a1-Dkk1 transgene significantly lowered whole body 
BMD, BMC, and vertebral BV/TV in wild-type mice and affected p.A214V mice more than 
p.G171V mice. These in vivo data support in vitro studies regarding the mechanism of HBM-
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causing mutations, and imply that HBM LRP5 receptors differ in their relative sensitivity to 
inhibition by SOST and DKK1.
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Introduction
The recent discovery and elucidation of the importance of WNT signaling in bone 
metabolism has presented new opportunities for the development of treatment options for 
osteoporosis, fracture healing, and other skeletal disorders (1). The crucial role of WNT 
signaling in normal, healthy bone tissue was demonstrated initially when the genetic cause 
of the Osteoporosis Pseudoglioma syndrome (OPPG) was identified. This autosomal 
recessive disease characterized by low bone mass and blindness is caused by loss-of-
function mutations affecting the WNT co-receptor LDL-Receptor-Related Protein 5 
(LRP5) (2, 3). Investigation into the cause of high bone mass (HBM) phenotypes in humans 
next identified missense mutations in LRP5, suggesting that gain- and loss-of function 
mutations in this receptor have substantial and opposing effects on bone mass and strength. 
A similar role in modulating bone mass has been demonstrated for LRP6, a closely related 
paralog of LRP5, underscoring the importance of WNT signaling in general for attainment 
of peak bone mass (4–7).
That missense mutations in LRP5 produce an HBM phenotype prompted investigation into 
the mechanism by which these single amino acid changes alter the receptor’s ability to 
transduce WNT signals. In vitro cell transfection experiments found that most HBM LRP5 
receptors respond normally to agonistic WNT ligands, but are less inhibited by endogenous 
LRP5 antagonists, including Dickkopf homolog-1 (DKK1) and sclerostin (SOST) (8–12). 
Consistent with these findings, LRP5 HBM mutations cluster in the first β-propeller domain 
surrounding the structurally mapped SOST “NxI” motif binding pocket (13). Similar to 
SOST, DKK1 also has an “NxI” motif that binds to the first β-propeller (13, 14), but DKK1 
also has an additional domain that binds to the third β-propeller of LRP5/6 (15–17). It is 
unclear which LRP5/6 binding domain in DKK1 is responsible for the majority of its 
endogenous inhibitory function (18). A second mechanism has been proposed for at least one 
HBM LRP5 mutation, p.G171V, which implicates impaired trafficking to the cell membrane 
but retention of the receptor’s WNT signal transduction ability. This second mechanism 
implies that resistance to SOST and DKK1 is due to less LRP5 reaching the cell surface, 
rather than to reduced affinity between LRP5 and its extracellular inhibitors (19). A 
limitation for all in vitro studies is that they have been performed in cells that overexpress 
LRP5.
In the present communication, we assess the in vivo actions of SOST and DKK1 in mice that 
have Lrp5 HBM-causing knock-in alleles. We explored this interaction by cross-breeding 
(A) transgenic mice that overexpress murine DKK1 in osteoblasts and osteocytes 
(2.3kbCol1a1-Dkk1) with knock-in mice that harbor either the p.G171V or p.A214V 
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mutation in Lrp5; and (B) transgenic mice that overexpress human SOST in osteocytes 
(8kbDmp1-SOST) with Lrp5 p.G171V or p.A214V knock-in mice. The 2.3kbCol1a1-Dkk1 
and 8kbDmp1-SOST transgenic mice exhibit an osteopenic phenotype (20, 21), whereas the 
Lrp5 HBM knock-in mice exhibit a high bone mass phenotype (22).
Based on previously published in vitro work, we anticipated that bone in Lrp5 HBM knock-
in mice would be protected from the osteopenic effects caused by overexpression of SOST 
and possibly protected from the effects caused by DKK1 overexpression. Here, we report 
that SOST overexpression does not significantly reduce bone properties in Lrp5 HBM mice 




All animal procedures were performed in accordance with guidelines set by the Indiana 
University Institutional Animal Care and Use Committee.
Mice with the Lrp5 knock-in HBM mutations p.A214V and p.G171V have been described 
previously (22) as have Lrp5 knockout mice.(23) The HBM mice were on a mixed 129S1/
SvIMJ and C57Bl/6J background. 2.3kbCol1a1-Dkk1 transgenic mice have been described 
previously.(20) Briefly, a 2.3kb fragment of the rat Col1a1 promoter drives expression of 
mouse Dkk1 cDNA. The 2.3kbCol1a1-Dkk1 transgenic mice were on an FVB 
background. 8kbDmp1-SOST transgenic mice have been described previously (21). Briefly a 
12kb DNA fragment containing 8 kb of the 5′-flanking region, the first exon, the first intron, 
and 17 bp of exon 2 of the murine Dmp1 gene was used to drive expression of a human 
SOST cDNA. The 8kbDmp1-SOST mice were on a fixed C57Bl/6J background. Lrp5 HBM 
mice were crossed with 8kbDmp1-SOST and 2.3kbCol1a1-Dkk1 transgenic mice for several 
generations to generate mice that were homozygous for the Lrp5 alleles; i.e., Lrp5+/+ 
(henceforth denoted WT), Lrp5A214V/A214V (henceforth denoted Lrp5 A214V), or 
Lrp5G171V/G171V (henceforth denoted Lrp5 G171V) and either positive or negative for the 
SOST or Dkk1 transgene. WT mice were derived from the same litters as transgenic mice, 
within each Lrp5 background. The Lrp5, SOST, and Dkk1 alleles were identified in mice 
using standard PCR techniques on genomic DNA from tail clips. For each of the analyses, 8 
mice per group were used unless otherwise indicated.
Dual energy x-ray absorptiometry (DEXA)
Longitudinal characterization of whole body (excluding skull) bone mineral content (BMC) 
and areal bone mineral density (aBMD) were measured using PIXImus2 (GE Lunar). Mice 
were anesthetized with isoflurane (2% @ 1.5 liters/min) and placed in a prone position with 
limbs outstretched. Whole-body scans were collected every 2 wks, beginning at 4.5 wks and 
extending to 16.5 wks of age.
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The right femur and 5th lumbar vertebra were extracted from euthanized mice at 17 wks of 
age. The bones were fixed in 10% NBF for 2 days and then stored in 70% ethanol. At the 
time of scanning (Skyscan 1172, Bruker, Inc., Kontich, Belgium), the femurs were 
suspended in a tube containing a thermoreversible gel (Pluronic® F108) to securely 
immobilize the bones during the scan (24). Acquisition settings were 60 kV peak tube 
potential, 1000×524 camera size, 0.4° step size, 151-ms integration time, and a resolution of 
10.04 microns/pixel.(25) Trabecular bone was segmented from cortical bone manually using 
the Skyscan software CTAn. For both SOST and DKK1overexpression studies, the analysis 
region for L5 contained all trabecular bone between both growth plates (excluding the 
primary spongiosa). For the distal femur, different analysis regions or the secondary 
spongiosa were implemented for each study. For the 8kbDmp1-SOST Lrp5 HBM experiment, 
a region 275 slices (~2.76mm) in height was used. For the 2.3kbCol1a1-Dkk1 Lrp5 HBM 
experiment, a region 225 slices (~2.26mm) in height was used. Different sections were used 
for the two different transgenic mouse models, based on preliminary analyses of transgenic 
and non-transgenic mice that identified the metaphyseal portion most affected by each 
transgene.
Dynamic histomorphometry
Mice received intraperitoneal injections of bone-labeling fluorochromes over the course of 
the study. Oxytetracycline (60 mg/kg) was injected at 5 weeks, calcein (18 mg/kg) at 8 
weeks, and alizarin (20 mg/kg) at 12 weeks. Following µCT measurement, the L5 and femur 
were dehydrated in graded alcohols, cleared in xylene, and embedded in methylmethacrylate 
following standard protocols. Thick-cut sections were taken at the midshaft and ground 
down to ~30 µm. Unstained sections were digitally imaged on a fluorescence microscope 
using filter sets that provide excitation and emission for the tetracycline, calcein, and alizarin 
wavelengths. Digital images were imported into ImagePro Express (Media Cybernetics, 
Inc., Gaithersburg, MD) and the following histomorphometric measurements were recorded 
between the calcein and alizarin labels for the periosteal and endocortical surfaces: total 
perimeter (B.Pm), single label perimeter (sL.Pm), double label perimeter (dL.Pm), double 
label area (dL.Ar), total bone area and marrow area. The following results were calculated: 
mineral apposition rate (MAR = dL.Ar/dL.Pm/28 days), mineralizing surface (MS/BS = 
(0.5* sL.Pm + dL.Pm)/B.Pm*100 ), and bone formation rate (BFR/BS = MAR * MS/BS * 
3.65).
Measurements of serum carboxy-terminal collagen crosslinks (CtX)
Blood samples were collected from mice at 7 wks of age, allowed to clot for 30–60 min, and 
then centrifuged to separate blood components. Serum was frozen at −80°C. Serum 
crosslinks were measured using a commercially available plate assay (IDS Ratlaps EIA) 
following manufacturer’s instructions. Serum samples from seven mice per group were 
analyzed.
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The left femurs from the 17-wk-old euthanized mice were removed, wrapped in saline 
soaked gauze, and stored at −20°C. On the day of testing, the femurs were allowed to warm 
to room temperature for at least 2 hours. The femoral length was measured with digital 
calipers, then the femoral diaphysis was broken using a 3-point bending system 
(EnduraTEC) that recorded force and displacement (26). Based on these data, the structural 
properties ultimate force, stiffness, and energy to ultimate force were calculated using 
standard equations.
Immunoblotting
Protein was extracted from femoral diaphysis cortical tubes (marrow removed) and liver 
from 8-wk-old Lrp5 HBM, WT, and knockout mice. Tissue samples were homogenized in 
T-Per tissue protein extraction reagent (Thermo-Fisher Scientific, Waltham, MA, USA) 
using the FastPrep-24 Instrument (MP Biochemicals, Santa Ana, CA, USA) and then 
centrifuged at 10,000g for 5 minutes. The supernatant was collected and assayed for total 
protein using the Coomassie Plus Protein Assay kit (Pierce Biotechnology, Rockford, IL, 
USA). Fifteen µg aliquots of protein extract were separated by SDS-PAGE, transferred to 
PVDF, and probed with anti-LRP5 antibody (D5G4; Cell Signaling, Danvers, MA, USA) 
and anti-β-actin antibody (Sigma, St Louis, MO, USA) at a dilution of 1:1000. The blots 
were incubated in species-appropriate HRP-conjugated secondary antibodies and immune 
complexes were detected using the WesternBreeze chemiluminescence kit (Life 
Technologies, Grand Island, NY).
Statistical methods
Longitudinal data were analyzed by repeated measures ANOVA comparing transgenic to 
nontransgenic mice within a sex/Lrp5 genotype group. All other data were compared using 
student’s t-test for transgenic to nontransgenic mice within a sex/Lrp5 genotype group. 
Significance was taken at p < 0.05. All data are presented as mean ±SE.
Results
I. A214V and G171V mice are resistant to the osteopenic effects of SOST overexpression
To assess the suppressive effects of SOST overexpression on bone we first evaluated the 
effects of the 8kbDmp1-SOST transgene on whole body areal bone mineral density (aBMD) 
and content (BMC) in Lrp5 WT mice. Consistent with previous reports,(21) SOST 
overexpression resulted in a significant reduction in bone mass (Fig. 1 A&B; Fig S1). SOST 
overexpression reduced aBMD by 9% in Lrp5 WT males (p=0.002) and by 4% in Lrp5 WT 
females (p=0.063). In contrast SOST overexpression did not significantly reduce aBMD in 
either male or female Lrp5 A214V mice (p=0.11 and p=0.38), respectively) or G171V mice 
(p=0.42 and p=0.87, respectively) (Fig. 1A&B).
We next analyzed femora from 16 wk-old Lrp5 WT and Lrp5 HBM mice with and without 
the 8kbDmp1-SOST transgene. SOST overexpression reduced the distal femur trabecular 
bone volume fraction (BV/TV) by 70% in Lrp5 WT males (p<0.001) and by 40% in Lrp5 
WT females (p=0.02) (Fig. 1C&E). In contrast, SOST overexpression did not reduce distal 
Niziolek et al. Page 5









femur BV/TV by more than 15% in male or female Lrp5 A214V or G171V mice (p>0.05 for 
all comparisons); distal femur trabecular number and trabecular spacing also differed 
significantly when SOST was overexpressed in Lrp5 WT mice, but not when SOST was 
overexpressed in Lrp5 A214V or G171V mice (Table S1).
Analysis of the 5th lumbar vertebra (L5) revealed that SOST overexpression reduced 
trabecular bone mass by ~50% in male and female Lrp5 WT mice (p<0.001 for both sexes), 
but did not significantly reduce BV/TV in the Lrp5 HBM mice (Fig. 1D). Lrp5 HBM mice 
were not completely resistant to SOST overexpression, as assessed by examining other 
trabecular bone parameters (Table S1), but the effect of SOST overexpression in both Lrp5 
HBM mice was less than that observed in Lrp5 WT mice.
Fluorochrome labels injected prior to sacrifice allowed us to measure changes in bone 
formation rates induced by SOST overexpression within the Lrp5 WT and HBM 
backgrounds. The SOST transgene significantly decreased periosteal bone formation rates 
(BFR/BS) by 15% in male Lrp5 WT mice (p=0.03) and by 22% in female Lrp5 WT mice 
(p=0.03), but the transgene did not significantly affect BFR/BS in either Lrp5 HBM strain 
(Fig. 2A&B, Table S2). The transgene had the opposite effect on the endocortical surface 
(Table S2). SOST overexpression had no effect on CtX values in WT or HBM mice (Fig 
2C).
SOST overexpression had no effect on bone properties in Lrp5 WT or HBM mice when 
evaluated by three-point bending (Table S2).
II. A214V mice are more susceptible to the osteopenic effects of DKK1 overexpression 
than G171V mice
We next assessed the suppressive effects of DKK1 overexpression on bone properties in 
Lrp5 WT and HBM mice. Consistent with previous reports of an osteopenic phenotype in 
these mice,(20) the 2.3kbCol1a1-Dkk1 transgene significantly reduced whole body aBMD and 
BMC in Lrp5 WT mice (Fig. 3A&B; Fig S2). DKK1 overexpression reduced aBMD by 7% 
in Lrp5 WT males (p=0.02) and by 9% in WT females (p<0.001) (Fig. 3A&B). A similar 
magnitude effect of DKK1 overexpression was observed in Lrp5 A214V mice (11% 
reduction in females and 14% reduction in males; p<0.001 for both sexes), and in female 
(7% reduction; p=0.008), but not male (0.2% reduction; p=0.94 ) Lrp5 G171V mice.
In the distal femoral metaphysis, DKK1 overexpression in Lrp5 WT mice reduced trabecular 
BV/TV by 58% and 38% in females and males, respectively (p=0.006 for females, p=0.07 
for males; Fig. 3C). Femoral BV/TV was similarly suppressed by the Dkk1 transgene in 
female and male Lrp5 A214V mice (32% and 33%, p=0.009 and p=0.004 respectively), but 
not in either female or male G171V mice (Fig. 3C&E). Although the 2.3kbCol1a1-Dkk1 
transgene significantly reduced vertebral BV/TV in Lrp5 WT mice, it did not in Lrp5 HBM 
mice (Fig. 3D). Other µCT-derived parameters for femoral and vertebral trabecular structure 
affected A214V mice to a greater extent than G171V mice (Table S3).
When we measured bone formation rates, we did not observe consistent data in males and 
females for any Lrp5 and Dkk1 transgene group (Fig. 4A and Table S4). We also did not 
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detect Dkk1-induced differences in CtX values in Lrp5 WT or HBM mice (Fig. 4B). 
Although the 2.3kbCol1a1-Dkk1 transgene did not significantly reduce bone mechanical 
properties in Lrp5 WT mice, it did reduce energy to ultimate force, ultimate force, and 
stiffness in male and female A214V mice and ultimate force and stiffness in female, but not 
male, G171V mice (Fig. 4C and Table S4).
III. A214V and G171V HBM receptors are expressed similarly in bone
Since in vitro studies of Lrp5 HBM alleles involved overexpression of the receptors and 
their chaperones (e.g., MESD) in cultured cells, we examined the endogenous level of LRP5 
receptor in protein extracts from diaphyseal bone and from liver in Lrp5 WT, knockout, 
A214V, and G171V mice (Fig. 5). As expected, no immunodetectable protein was present in 
knockout mice. Two immunoreactive bands were detected in WT, A214V, and G171V 
mice, which likely represent post-translational modification by glycosylation.(27) We did not 
observe a consistent difference in the abundance of LRP5 receptor in protein extracts from 
WT and HBM mouse liver or bone. However, we were unable to reliably quantify cell 
surface receptor levels using techniques such as biotinylation (data not shown) and, 
consequently, could not determine whether there was a difference in the abundance of 
A214V and G171V receptor at the cell surface.
Discussion
This study addresses one mechanism by which Lrp5 HBM-causing mutations affect bone 
properties, which is by making the LRP5 receptor less susceptible to antagonism by 
endogenous inhibitors. We tested this mechanism in vivo using mice with knock-in HBM 
alleles of Lrp5 and with transgenes overexpressing the secreted inhibitors SOST and DKK1. 
We used two different promoters to drive expression of the secreted inhibitors. SOST is 
normally expressed by osteocytes; thus we used an osteocyte-specific promoter (8kbDmp1) 
to drive that transgene. In bone tissue, DKK1 is expressed more broadly—by osteocytes and 
osteoblasts; thus we used the osteoblast and osteocyte selective 2.3kbCol1a1 promoter to 
drive that transgene. The different promoter strategy we used for these experiments had the 
advantage of more closely recapitulating the naturally occurring cell-specific expression 
profile. However, this strategy had the disadvantage of precluding direct comparisons 
between DKK1 and SOST overexpression. The 8kbDmp1-SOST mouse model exhibits a 1.3-
fold increase in SOST transcript abundance and a 1.6-fold increase in total (murine + human) 
SOST protein in bone (21). In contrast, the 2.3kbCol1a1-Dkk1 mouse model exhibits a ~20-
fold increase in Dkk1 mRNA expression compared non-transgenic animals, though the 
effect on DKK1 protein abundance was not reported (20).
We confirmed that SOST overexpression reduced bone properties in Lrp5 WT mice and 
found that it did not significantly reduce bone properties in either the Lrp5 A214V or the 
G171V HBM mice. Several measures of bone formation and bone mass decreased non-
significantly when SOST was overexpressed in Lrp5 HBM mice, likely due to the inhibitory 
action of SOST on LRP6 which also affects bone mass in mice.(28) However, the bone 
properties in mice with Lrp5 HBM alleles and SOST overexpression remained substantially 
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higher than those of WT mice, indicating that the effect of the HBM LRP5 receptor 
supersedes that of LRP6 in this context.
Similar, but not identical, results were obtained when DKK1 was overexpressed. DKK1 
overexpression tended to reduce bone properties in Lrp5 WT mice, but reached significance 
in males and females only for measures of aBMD, BMC, 5th lumbar vertebra BV/TV, and 
trabecular number in the distal femur and lumbar vertebra. In contrast to SOST 
overexpression, where Lrp5 A214V and G171V mice were equally resistant, Lrp5 A214V 
HBM mice were less resistant to the effects of DKK1 overexpression than G171V mice. For 
example, DKK1 overexpression in male and female Lrp5 A214V mice caused significant 
reductions in aBMD, distal femur BV/TV, distal femur and vertebral body trabecular 
number, and ultimate force in 3-point bending tests, whereas no consistent reductions were 
observed in the Lrp5 G171V mice. Even when DKK1 overexpression reduced bone 
properties in Lrp5 HBM mice, the resultant bone properties were still substantially higher 
than those of WT mice. This observation suggests that substantial HBM LRP5 receptor 
signaling and bone mass accrual occur before the Dkk1 transgene becomes expressed, or at 
sites or in cells that are less susceptible to DKK1 overexpression by osteoblasts and 
osteocytes.
Our in vivo data are consistent with in vitro studies that implicated decreased inhibition by 
SOST as the primary mechanism by which all known Lrp5 HBM mutations produce 
increased bone mass, (29–31) and with our previous in vivo studies showing similarity 
between Sost−/− and Lrp5 HBM mutant mouse model phenotypes.(32) The data also suggest 
that some HBM LRP5 receptor mutations can affect the sensitivity of the receptor to 
inhibition by DKK1, but this result is less certain. Various scenarios may account for the 
difference between Lrp5 A214V and G171V mice in their response to DKK1 
overexpression. First, DKK1 binds both the first and the third β-propeller of 
LRP5/6 (15, 19, 33), and consequently might be expected to only partially alter receptor 
function when missense mutations are introduced into the first β-propeller alone. Several 
studies have reported impaired DKK1 binding and/or DKK1-mediated inhibition of WNT 
signaling for the G171V and A214T HBM LRP5 mutants.(9, 10, 12, 34) However, others 
showed that DKK1 inhibits G171V and A214T similar to WT LRP5 when compared in 
parallel with mutations in the third beta propeller.(11, 19) However, all in vitro studies are 
limited in that the conditions used to assess DKK1 and LRP5 interaction may not have been 
physiologically relevant.(35) Our in vivo data suggest that under physiologic conditions 
DKK1 overexpression inhibits A214V differently than G171V.
Second, it has also been suggested that G171V mutant receptors do not traffic normally to 
the cell surface, leaving the receptor capable of transducing intracellular WNT signals while 
being resistant to extracellular DKK1 or SOST.(19) Again, since this mechanism was 
proposed based on in vitro overexpression experiments, the in vivo relevance is uncertain. 
We performed western blot analyses of LRP5 extracted from liver and cortical diaphyseal 
bone of Lrp5 WT, knockout, A214V and G171V mice. It has previously been reported that 
LRP5/6 receptors within the secretory pathway migrate at ~180 kDa while receptor observed 
at the plasma membrane migrates more slowly at ~200 kDa (27). The anti-LRP5 antibody we 
used did not detect LRP5 in knockout mice, indicating that the antibody is specific. We 
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observed immunodetectable LRP5 in bone and liver extracts from WT, A214V and G171V 
mice, but did not see any consistent differences between mice with the different genotypes. 
Importantly, each mouse had the larger molecular weight LRP5 band, likely representing 
receptor that has trafficked to the cell surface.(27) Although in vitro overexpression studies 
were able to identify cell-surface-localized LRP5 using biotinylation and 
immunoprecipitation,(27) we were unable to recover sufficient amounts of endogenous LRP5 
following biotinylation and IP of membrane proteins from cultured embryonic fibroblasts to 
determine whether the amount of receptor at the surface differed between mice with A214V 
and G171V alleles.
Third, we cannot preclude the possibility that background differences between the A214V 
and G171V strains account for their differing response to DKK1 overexpression by 
influencing the level of Dkk1 transgene expression and/or the relative contribution of LRP5 
and LRP6 to bone anabolism. Backcrossing all strains onto the same genetic background 
would minimize the effect of this variable in future experiments.
When an effect of DKK1 overexpression was found in G171V mice, it was only in females. 
These results could represent false positives caused by multiple hypothesis testing, since 
many bone parameters were analyzed, or could suggest sex-specific effects of the transgene 
or the Lrp5 allele. Sex-specific effects have been reported in mice harboring other mutations 
that affect WNT signaling. For example, female mice with osteocyte deletion (10kbDmp1-
Cre-mediated) of Ctnnb1 (which encodes β-catenin) are more severely affected than their 
male counterparts (36). Further, 17 β-estradiol, but not testosterone, inhibits the increase in 
SOST that normally accompanies sex steroid deficiency (37). It remains to be confirmed if 
and how Lrp5 HBM mutations affect cross-talk between the WNT and sex-steroid signaling 
pathways.
In conclusion, mice with Lrp5 A214V and G171V knock-in alleles are resistant to the 
osteopenic effects of SOST and DKK1 overexpression, although DKK1 overexpression does 
affect bone properties in A214V mice more than in G171V mice. These data provide in vivo 
support for the hypothesis that HBM mutations increase bone properties by reducing the 
endogenous inhibition of the LRP5 receptor. Still left to be determined is whether the 
resistance to inhibition of certain HBM-causing mutations is due to altered trafficking to the 
cell surface or altered binding to some endogenous inhibitors and not others. Studies that can 
precisely define the mechanism(s) of action for HBM-causing mutations have the potential 
to yield improved therapies for augmenting bone mass and preventing fractures.
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The mechanism of action for High Bone Mass (HBM)-causing mutations in the LRP5 
receptor have been postulated to occur via reduced inhibition by secreted LRP5/6 
antagonists, based on cell culture overexpression models. Anti-sclerostin and anti-DKK1 
antibody therapies are being developed to build bone and prevent fractures among 
individuals with various diseases of low bone mass, most notably osteoporosis. Here we 
show in an in vivo model that sclerostin overexpression fails to manifest its osteopenic 
effects in two Lrp5 HBM knock-in mouse mutants – G171V and A214V. However, 
DKK1 overexpression has osteopenic effects in A214V but not G171V mutant mice. The 
data highlight the existence of multiple mechanisms of action for HBM-causing alleles of 
Lrp5, in an in vivo context.
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Whole body areal bone mineral density (aBMD) measured every 2 wks, beginning at 4.5 
wks of age and ending at 16.5 wks of age, in (A) Lrp5 A214V mutant mice (A/A), and in 
(B) Lrp5 G171V mutant mice (G/G), with (+) or without (-) the 8kbDmp1-SOST transgene. 
*p<0.05 from a repeated measures ANOVA for the SOST transgene main effect within Lrp5 
genotype. Trabecular bone volume fraction (BV/TV) in (C) the distal femoral metaphysis 
and (D) the fifth lumbar vertebra, from 17-wk-old male and female Lrp5 +/+, A/A, and G/G 
mice, with (TG) or without (NTG) the 8kbDmp1-SOST transgene. *p<0.05 NTG vs TG 
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within same Lrp5/sex group. Additional µCT parameters are reported in supplemental Table 
S1. (E) Representative cut-away µCT images of the distal femur from the groups indicated 
in panel C. Note the reduced trabecular bone mass induced by the SOST transgene and the 
increase in bone mass induced by the Lrp5 HBM alleles. Lrp5 WT data are repeated across 
graphs within panels A and B (for each sex) for clarity of the Lrp5 HBM curves. Sample 
sizes for the DEXA data (A and B) and the µCT data (C and D) are n=8/group.
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Bone formation and resorption indices male and female Lrp5 WT (+/+), Lrp5 A214V 
homozygous knock-in (A/A), and Lrp5 G171V homozygous knock-in (G/G) mice, with (+) 
or without (−) the 8kbDmp1-SOST transgene. (A) Periosteal bone formation rate per unit 
bone surface (BFR/BS) was measured over the post-weaning growth phase of the mice using 
an oxytetracycline label administered at 5 wks and an alizarin complexone label 
administered at 12 wks. (B) Whole bone and close-up photomicrographs of the 
fluorochrome labeling (male mice are shown) from the experimental groups showing 
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periosteal bone formation. The central label is a calcein label administered at 8 wks, which 
was not used for the measurements shown in panel A. Histomorphometric measurements 
using this label as the first label, rather than the tetracycline label, produced nearly identical 
results as those generated using the tetracycline label (data not shown). (C) Serum collected 
at 7 wks of age was assayed for the resorption marker carboxy-terminal collagen crosslinks 
(CtX). *=p<0.05 TG vs NTG within same Lrp5/sex group. Additional histomorphometric 
parameters are reported in supplemental Table S2. Sample sizes are indicated along the x-
axis.
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Whole body areal bone mineral density (aBMD) measured every 2 wks, beginning at 4.5 
wks of age and ending at 16.5 wks of age, in (A) Lrp5 A214V mutant mice (A/A), and in 
(B) Lrp5 G171V mutant mice (G/G), with (+) or without (−) the 2.3kbCol1a1-Dkk1 
transgene. *p<0.05 from a repeated measures ANOVA for the Dkk1 transgene main effect 
within Lrp5 genotype. Trabecular bone volume fraction (BV/TV) in (C) the distal femoral 
metaphysis and (D) the fifth lumbar vertebra, from 17-wk-old male and female Lrp5 +/+, 
A/A, and G/G mice, with (TG) or without (NTG) the 2.3kbCol1a1-Dkk1 transgene. *p<0.05 
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NTG vs TG within same Lrp5/sex group. Additional µCT parameters are reported in 
supplemental Table S3. (E) Representative cut-away µCT images of the distal femur from 
the groups indicated in panel C. Note the reduced trabecular bone mass induced by the Dkk1 
transgene and the increase in bone mass induced by the Lrp5 HBM alleles. Lrp5 WT data 
are repeated across graphs within panels A and B (for each sex) for clarity of the Lrp5 HBM 
curves. Sample sizes for the DEXA data (A and B) and the µCT data (C and D) are n=8/
group.
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Periosteal bone formation rates, serum resorption indices, and whole bone mechanical 
properties in male and female Lrp5 WT (+/+), Lrp5 A214V homozygous knock-in (A/A), 
and Lrp5 G171V homozygous knock-in (G/G) mice, with (+) or without (−) 
the 2.3kbCol1a1-Dkk1. (A) Periosteal bone formation rate per unit bone surface (BFR/BS) 
was measured over the post-weaning growth phase of the mice using an oxytetracycline 
label administered at 5 wks and an alizarin complexone label administered at 12 wks. (B) 
Serum collected at 7 wks of age was assayed for the resorption marker carboxy-terminal 
collagen crosslinks (CtX). (C) Energy to ultimate force derived from monotonic three-point 
bending tests to failure of femora from 17-wk-old male and female mice. *=p<0.05 TG vs 
NTG within same Lrp5/sex group. Sample sizes are indicated along the x-axis. Additional 
histomorphometric and biomechanical properties are reported in supplemental Table S4.
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Immunodetection of endogenous LRP5 from wild-type, knockout, and HBM mice. Protein 
lysates recovered from diaphyseal cortical bones, liver, or cultured mouse embryonic 
fibroblasts (MEF) were separated by SDS-PAGE on 4 – 12% gradient gels, transferred to 
PVDF, and immunodetected with an anti-LRP5 antibody followed by an anti-βactin 
antibody, as a loading control. Note the absence of immunoreactive bands in the Lrp5 
knockout (−/−) mice. Comparable amounts of immunodetectable LRP5 in WT (+/+) and 
HBM (G/G and A/A) mice are present in bones from different mice with each genotype (left 
of center panels); the same was found for LRP5 from liver and MEFs (right of center 
panels). At present, we do not know whether the two immunoreactive LRP5 bands seen in 
some blots represent the receptor’s post-translational modification during its trafficking to 
the cell surface,(27) its different post-translational modifications tissues with multiple cell 
types, or its partial degradation during extraction.
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